based Ionis soared 30.2% to close at $38.01. Biogen has paid Ionis a $75-million licensing fee for the drug, called nusinersen, Ionis Chief Executive Stanley T. Crooke said. The Cambridge ...

Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...

Biogen and Ionis Pharmaceuticals’ Spinraza ... According to an interim analysis, Spinraza (nusinersen) met primary endpoint in later-onset (consistent with Type 2) SMA.

Biogen Inc. (Nasdaq: BIIB) today announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for SPINRAZA (nusinersen) on the National ...

A trial studying a higher dose of Biogen’s spinal muscular atrophy (SMA) drug Spinraza (nusinersen) has met the primary endpoint in a cohort of infants with SMA. Data from the Phase II/III ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

Biogen has shared positive top-line results from a phase 2/3 study evaluating a higher dose regimen of its antisense oligonucleotide nusinersen in spinal muscular atrophy (SMA). The drug is already ...

Treatment with nusinersen was linked to increased motor ... Proud reports serving on advisory boards and as a consultant for AveXis, Biogen, and Sarepta; serving as a speaker for AveXis and ...

The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA (nusinersen ... Also Read: Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst ...

FY24 EPS is projected at $16.34. The FDA approved maintenance dosing regimen for Leqembi in Alzheimer's, while Biogen's nusinersen higher-dose regimen is under review. Unlock your all-in-one ...